CD8A and hepatocellular carcinoma: They developed and validated a nine-factor IHC classifier (CD27T, CD57T, CD57P, CD45RAP, CD45ROT, CD66bT, CD68P, CXCR5P, and PD-1T) to predict recurrence in patients with early-stage HCC, but neither CD3 nor CD8 entered the final model.